• FirefoxUpgrade to the new Firefox »
  •  Dow Down1.45% Nasdaq Down1.03%

    More On BIO.DE



    News & Info


    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Biotest AG (BIO.DE)

    98.50 Up 1.10(1.13%) Jan 30, 11:35AM EST
    Add to Portfolio
    ProfileGet Profile for:
    Biotest AG
    Landsteinerstrasse 5
    Dreieich, 63303
    Germany - Map
    Phone: 49 6103 801 4406
    Fax: 49 6103 801 347
    Website: http://www.biotest.de

    Index Membership:N/A
    Full Time Employees:2,137

    Business Summary 

    Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Biotest AG

    Key Executives 
    Dr. Michael Ramroth ,
    Chief Financial Officer, Head of Fin.s & Central Services and Member of the Management Board
    Dr. Georg Floss ,
    Chief Operating Officer and Member of Exec. Board
    Dr. Bernhard R. M. Ehmer M.D., 60
    Chief Exec. Officer and Chairman of Management
    Dr. Monika Buttkereit ,
    Head of Investor Relations
    Dr. Joachim Herborg ,
    Head of Marketing and Distribution Division
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in EUR.